Searched for
AIOCD AWACS
Sun Pharma eyes acquisitions in US, Europe and emerging marketsWith a market share of 8.1% as per market research firm AIOCD-AWACS in September 2021, Sun Pharma has the highest share in the domestic pha...- Drug sales show the times are bad for mental healthData sourced from market research firm AIOCD-AWACS show a 13% year-on-year jump in sales of CNS (central nervous system) drugs for the June...
- DigiHealth acquires Pharmarack and market research firm AIOCD AWACS for better IT infra playThe company looks to build the IT infrastructure and supply chain required for pharma distribution.
- Panic buying of drugs down since mid-AprilSales of anti-infective medicines in the April 1-22 period eased to 62% from levels seen from March 1to 22. While sales of antidiabetes dru...
- GST may not impact essential drugs stockRecently, pharma research firm, AIOCD Awacs which tracks seven lakh chemists, also said it did not foresee shortages at the consumer level.
- NPPA identifies 634 suspected cases of overchargingAs stipulated under the Drugs (Prices Control) Order (DPCO) 2013, NPPA fixes ceiling price of essential medicines of Schedule I.
- Five diabetes drugs in top-10 selling list; overtakes anti-infective, antibiotic medsInsulin brand Human Mixtard, oral formulation Glycomet GP, insulin Lantus, oral formulations Galvus Met and Janumet are now in the top-sell...
- Pharma sector grows 7.7 per cent in May; FDC ban weighsUnder the non-NLEM category, growth in May for domestic players and MNCs almost doubled to 9 per cent and 7.1 pc as against April's 4.6 pc ...
- NPPA cuts antibiotic, stomach ulcer and abortion drug prices by 30%Indian drug pricing watchdog National Pharmaceutical Pricing Authority (NPPA) has cut prices of 24 more essential medicines.
- Pharmaceutical companies refute Congress' post claiming hike in prices of life-saving drugsNovartis, which owns patent for Glivec globally but excluding India, and Natco Pharma, whose generic version of drug was also listed on web...
- Sun-Ranbaxy combine to control over 40% market for 25 drugsFor nine drugs its market share will be more than 65% and in another 15 it will be 40-60%, revealed an analysis of the latest data.
- Lundbeck to seek legal recourse after health ministry bans Deanxit againThe government had first banned the drug in June last year after noting that it was not approved for marketing in several developed markets.
- How does the Sun Pharma-Ranbaxy deal change the game for the other players in the Indian pharma market?The combined market share of Sun Pharma (5.4% at present) and Ranbaxy (3.8%) will be 9.2%; much higher than that of the current No. 1 playe...
- Sun Pharma-Ranbaxy combine creates a new market leader in Indian marketThe proposed new entity would unseat Abbott from the top position, which holds current market share of 6.5%, according to research firm Aio...
- Government may have to reset prices of essential drugsThe government may have to go back to the drawing board and reset prices of essential drugs, adding to the prevailing confusion in the dome...
- Slowdown grips domestic pharma market, records sluggish growth for OctoberThe domestic pharma industry is now witnessing a big slowdown with October becoming the third consecutive month to record sluggish growth.
- Slowdown hits domestic pharma, market shrinks 1.8 per cent in SeptemberThe economic slowdown has hit the Rs 72,000- crore domestic pharma business, usually considered recession-proof.
- Pharma industry hit by worst slowdown in the domestic market for the month of AugustThe Indian pharma industry, while being on a roll due to the higher export realisations due to the weaker rupee, has suffered badly in the ...
- ‘Essential Drugs’ price-cut may cost pharma sector 920 croreThe national pharma price authority notified prices of 151 essential drugs on June 17.
- Data shows slowdown in the domestic pharma marketDecember 2012 has been the month with one of the lowest growth rates in a long period of time.
Load More
